Heron Therapeutics Statistics
Total Valuation
HRTX has a market cap or net worth of $263.12 million. The enterprise value is $370.48 million.
Important Dates
The next confirmed earnings date is Thursday, February 27, 2025, before market open.
| Earnings Date | Feb 27, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
HRTX has 152.09 million shares outstanding. The number of shares has increased by 16.83% in one year.
| Current Share Class | 152.09M |
| Shares Outstanding | 152.09M |
| Shares Change (YoY) | +16.83% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 0.71% |
| Owned by Institutions (%) | 52.87% |
| Float | 115.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.91 |
| Forward PS | 1.74 |
| PB Ratio | -6.58 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.69 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.28
| Current Ratio | 2.28 |
| Quick Ratio | 1.61 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.75 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -2.31% |
| Return on Invested Capital (ROIC) | -3.58% |
| Return on Capital Employed (ROCE) | -6.15% |
| Revenue Per Employee | $1.09M |
| Profits Per Employee | -$221,960 |
| Employee Count | 126 |
| Asset Turnover | 0.61 |
| Inventory Turnover | 1.65 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.72% in the last 52 weeks. The beta is 1.61, so HRTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.61 |
| 52-Week Price Change | -39.72% |
| 50-Day Moving Average | 1.66 |
| 200-Day Moving Average | 2.20 |
| Relative Strength Index (RSI) | 52.85 |
| Average Volume (20 Days) | 1,178,754 |
Short Selling Information
The latest short interest is 30.84 million, so 20.28% of the outstanding shares have been sold short.
| Short Interest | 30.84M |
| Short Previous Month | 31.06M |
| Short % of Shares Out | 20.28% |
| Short % of Float | 26.63% |
| Short Ratio (days to cover) | 20.83 |
Income Statement
In the last 12 months, HRTX had revenue of $137.74 million and -$27.97 million in losses. Loss per share was -$0.18.
| Revenue | 137.74M |
| Gross Profit | 65.36M |
| Operating Income | -8.32M |
| Pretax Income | -48.13M |
| Net Income | -27.97M |
| EBITDA | -5.70M |
| EBIT | -8.32M |
| Loss Per Share | -$0.18 |
Full Income StatementBalance Sheet
The company has $70.89 million in cash and $178.25 million in debt, giving a net cash position of -$107.36 million or -$0.71 per share.
| Cash & Cash Equivalents | 70.89M |
| Total Debt | 178.25M |
| Net Cash | -107.36M |
| Net Cash Per Share | -$0.71 |
| Equity (Book Value) | -40.01M |
| Book Value Per Share | -0.26 |
| Working Capital | 109.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$8.29 million and capital expenditures -$1.32 million, giving a free cash flow of -$9.61 million.
| Operating Cash Flow | -8.29M |
| Capital Expenditures | -1.32M |
| Free Cash Flow | -9.61M |
| FCF Per Share | -$0.06 |
Full Cash Flow StatementMargins
Gross margin is 47.45%, with operating and profit margins of -6.04% and -20.30%.
| Gross Margin | 47.45% |
| Operating Margin | -6.04% |
| Pretax Margin | -20.30% |
| Profit Margin | -20.30% |
| EBITDA Margin | -4.13% |
| EBIT Margin | -6.04% |
| FCF Margin | n/a |
Dividends & Yields
HRTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.83% |
| Shareholder Yield | -16.83% |
| Earnings Yield | -10.63% |
| FCF Yield | -3.65% |
Analyst Forecast
The average price target for HRTX is $5.67, which is 227.75% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $5.67 |
| Price Target Difference | 227.75% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 13.88% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on January 13, 2014. It was a reverse split with a ratio of 0.05:1.
| Last Split Date | Jan 13, 2014 |
| Split Type | Reverse |
| Split Ratio | 0.05:1 |
Scores
HRTX has an Altman Z-Score of -10.32 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -10.32 |
| Piotroski F-Score | 3 |